NASDAQ:VERV

Verve Therapeutics Stock Forecast, Price & News

$69.87

+5.35 (+8.29 %)

(As of 09/16/2021 12:00 AM ET)

Add

Compare

Today's Range

$64.83

▼

$69.91

50-Day Range

$46.00

▼

$73.99

52-Week Range

$29.50

▼

$78.00

Volume538,405 shs

Average Volume420,156 shs

Market Capitalization$3.35 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive VERV News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Verve Therapeutics

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is based in Cambridge, Massachusetts.

Verve Therapeutics (NASDAQ:VERV) Shares Gap Up to $64.52
September 16, 2021 | americanbankingnews.com

Cathie Wood Bets Big on These 2 “Strong Buy” Stocks
September 15, 2021 | finance.yahoo.com

Verve Therapeutics (NASDAQ:VERV) Stock Price Down 8.2%
September 13, 2021 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Shares Gap Up to $70.07
September 9, 2021 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Reaches New 1-Year High at $77.73
September 7, 2021 | americanbankingnews.com

William Blair Reaffirms "Buy" Rating for Verve Therapeutics (NASDAQ:VERV)
September 2, 2021 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Hits New 52-Week High at $74.44
August 30, 2021 | americanbankingnews.com

Verve Therapeutics: Battling Bad Cholesterol with Single Treatment
August 29, 2021 | nasdaq.com

Verve Therapeutics (NASDAQ:VERV) Stock Price Up 6.3%
August 26, 2021 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Shares Gap Down to $63.44
August 25, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VERV
Previous Symbol
CUSIPN/A
CIKN/A
Webvervetx.com
Phone978-501-3026
Employees63
Year FoundedN/A

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares47,992,000
Market Cap$3.35 billion
Next Earnings Date11/11/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.44 out of 5 stars

Medical Sector

948th out of 1,352 stocks

Pharmaceutical Preparations Industry

464th out of 665 stocks

1.4 Analyst's Opinion

Consensus Rating
Verve Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $74.50, Verve Therapeutics has a forecasted upside of 6.6% from its current price of $69.87.
Amount of Analyst Coverage
Verve Therapeutics has only been the subject of 4 research reports in the past 90 days.

5.0 Community Rank

Outperform Votes
Verve Therapeutics has received 4 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Verve Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Verve Therapeutics has received 100.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Verve Therapeutics and other stocks. Vote “Outperform” if you believe VERV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VERV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Verve Therapeutics does not currently pay a dividend.
Dividend Growth
Verve Therapeutics does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Verve Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Institutions
55.59% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Verve Therapeutics are expected to decrease in the coming year, from ($0.35) to ($2.48) per share.

See Top Rated MarketRank™ Stocks Here

Verve Therapeutics (NASDAQ:VERV) Frequently Asked Questions

Is Verve Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Verve Therapeutics stock.
View analyst ratings for Verve Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Verve Therapeutics?

Wall Street analysts have given Verve Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Verve Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Verve Therapeutics' next earnings date?

Verve Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Verve Therapeutics.

How were Verve Therapeutics' earnings last quarter?

Verve Therapeutics, Inc. (NASDAQ:VERV) announced its earnings results on Thursday, August, 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $1.60.
View Verve Therapeutics' earnings history.

What price target have analysts set for VERV?

4 Wall Street analysts have issued 1 year price targets for Verve Therapeutics' stock. Their forecasts range from $50.00 to $92.00. On average, they expect Verve Therapeutics' stock price to reach $74.50 in the next year. This suggests a possible upside of 6.6% from the stock's current price.
View analysts' price targets for Verve Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Verve Therapeutics' key executives?

Verve Therapeutics' management team includes the following people:

Dr. Burt A. Adelman M.D., Co-Founder & Independent Chairman (Age 69, Pay $60k)
Dr. Sekar Kathiresan, Co-Founder, CEO & Director (Age 49, Pay $721.99k)
Mr. Andrew D. Ashe J.D., Pres & COO (Age 54, Pay $532.69k)
Dr. Anthony Philippakis Ph.D., M.D., Co-Founder
Dr. Andrew Bellinger, Chief Scientific Officer (Age 43, Pay $487.59k)
Dr. Kiran Musunuru M.P.H., M.D., Ph.D., Co-Founder & Sr. Scientific Advisor
Dr. J. Keith Joung, Co-Founder
Dr. Barry S. Ticho FACC, M.D., Ph.D., Co-Founder (Age 61)
Mr. Issi Rozen, Co-Founder & Strategic Advisor
Ms. Margaret Beaudoin, VP of Fin. (Age 52)

Who are some of Verve Therapeutics' key competitors?

Some companies that are related to Verve Therapeutics include Maravai LifeSciences (MRVI), Zai Lab (ZLAB), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), CureVac (CVAC), Bausch Health Companies (BHC), Grifols (GRFS), Teva Pharmaceutical Industries (TEVA), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Biohaven Pharmaceutical (BHVN), Mirati Therapeutics (MRTX), Evotec (EVTCY), Jazz Pharmaceuticals (JAZZ) and BridgeBio Pharma (BBIO).
View all of VERV's competitors.

When did Verve Therapeutics IPO?

(VERV) raised $201 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO.

What is Verve Therapeutics' stock symbol?

Verve Therapeutics trades on the NASDAQ under the ticker symbol "VERV."

When did the company's quiet period expire?

Verve Therapeutics' quiet period expired on Tuesday, July 27th. Verve Therapeutics had issued 14,035,789 shares in its public offering on June 17th. The total size of the offering was $266,679,991 based on an initial share price of $19.00. During the company's quiet period, underwriters and any insiders involved in the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Verve Therapeutics' major shareholders?

Verve Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (7.48%), Redmile Group LLC (4.20%), JPMorgan Chase & Co. (2.00%), RA Capital Management L.P. (1.91%), Citadel Advisors LLC (1.80%) and Logos Global Management LP (1.64%). Company insiders that own Verve Therapeutics stock include Cormorant Asset Management, Lp and Logos Global Management Lp.

Which major investors are buying Verve Therapeutics stock?

VERV stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Redmile Group LLC, JPMorgan Chase & Co., RA Capital Management L.P., Citadel Advisors LLC, Logos Global Management LP, Price T Rowe Associates Inc. MD, and ARK Investment Management LLC. Company insiders that have bought Verve Therapeutics stock in the last two years include Cormorant Asset Management, Lp, and Logos Global Management Lp.

How do I buy shares of Verve Therapeutics?

Shares of VERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verve Therapeutics' stock price today?

One share of VERV stock can currently be purchased for approximately $69.87.

How much money does Verve Therapeutics make?

Verve Therapeutics has a market capitalization of $3.35 billion.

How many employees does Verve Therapeutics have?

Verve Therapeutics employs 63 workers across the globe.

What is Verve Therapeutics' official website?

The official website for Verve Therapeutics is vervetx.com.

How can I contact Verve Therapeutics?

The company can be reached via phone at 978-501-3026 or via email at [email protected]

This page was last updated on 9/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here